Epilepsy is a chronic brain disorder characterized by recurring seizures, which are episodes of uncontrolled and abnormal electrical activity in the brain that can cause changes in behavior, sensations, awareness, and movement.  Epilepsy has a wide range of consequences, impacting neurobiology, cognition, and psychosocial well-being. To support drug discovery teams focused on epilepsy research, our …Read More >

Rare neurological diseases are conditions affecting the nervous system that occur infrequently, with examples including Huntington’s disease, Rett syndrome, and Amyotrophic Lateral Sclerosis (ALS). These rare disorders can be classified into various categories based on the affected systems/organs, among which, neuroinflammatory & neuroimmunology-related disorders, movement disorders, and motor neuron disease show higher prevalence. To support …Read More >

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors to evade the immune system. IDO1 can also suppress the immune response through mechanisms independent of its enzyme activity, and this may be difficult to target with current inhibitors.  Drugs targeting only IDO1 enzyme activity …Read More >

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies for overcoming paclitaxel resistance represents an unmet medical need. Although not fully understood, the mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce …Read More >

Asthma is a chronic, lower airway disease characterized by persistent inflammation and hyperreactivity. Asthma involves a complex immune response, with T-helper 2 (Th2) cells playing a central role, leading to activation of eosinophils and increased levels of IgE antibodies. Clinically, airflow obstruction in asthma often is not fully reversible, and many asthmatic subjects experience an …Read More >

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a combination therapy regimen for DLBCL that combines chemotherapy drugs with rituximab). Polatuzumab vedotin is an antibody-drug conjugate (ADC) used to treat DLBCL, both in first-line treatment and for relapsed or refractory cases. At the 2025 …Read More >

Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer therapies.  However, primary and secondary resistance is frequently observed.  The successful development of next generation ADCs necessitates the establishment of tumor models that address the mechanism of action underlying this resistance. At the 2025 World …Read More >

Abstract: Emerging as a major global health concern, metabolic dysfunction-associated steatohepatitis (MASH) is closely linked to obesity, type 2 diabetes, and other metabolic disorders. Advances in metabolic research have positioned glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising therapeutic option for MASH, extending their use beyond diabetes and obesity management. This article examines the …Read More >

Introduction In recognition of International Women’s Day, we spotlight women’s health—a continuously evolving global healthcare issue. The year 2025 marks the 30th anniversary of the United Nations Fourth World Conference on Women, where the landmark Beijing Declaration was adopted. This pivotal document systematically outlined an action framework for advocating women’s rights, with a particular emphasis …Read More >